SEC Company Response from ELITE PHARMACEUTICALS (ELTP) — Jul 11, 2016
ELITE PHARMACEUTICALS INC /NV/ (ELTP) (CIK 0001053369)
Date: July 11, 2016 · CIK: 0001053369 · Accession: 0001144204-16-112438
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212266
Letter
Office of Healthcare and Insurance Division of Corporation Finance Securities and Exchange Commission Re: Elite Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 27, 2016 File No. 333-212266
Dear MS. Hayes:
Elite Pharmaceuticals, Inc. (“Elite”) hereby requests, pursuant to Rule 461 of Regulation C, that the effective date of the above referenced Registration Statement be accelerated so that it is declared effective at 4:00 p.m. on July 13, 2016 or as soon thereafter as practicable.
Elite acknowledges that the disclosure in the filing is the responsibility of Elite.
Elite also represents to the Commission that should the Commission or the staff acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing and Elite represents that it will not assert Staff comments or this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Elite further acknowledges, that the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective does not relieve Elite from its full responsibility for the adequacy and accuracy of the disclosures in the filing.
Very truly yours,
ELITE PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
ELITE PHARMACEUTICALS, INC.
165 Ludlow Avenue
Northvale, NJ 07647
July 11, 2016
Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20002
Re:
Elite Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed June 27, 2016
File No. 333-212266
Dear MS. Hayes:
Elite Pharmaceuticals, Inc. (“Elite”)
hereby requests, pursuant to Rule 461 of Regulation C, that the effective date of the above referenced Registration Statement be
accelerated so that it is declared effective at 4:00 p.m. on July 13, 2016 or as soon thereafter as practicable.
Elite acknowledges that the disclosure in
the filing is the responsibility of Elite.
Elite also represents to the Commission
that should the Commission or the staff acting pursuant to delegated authority, declare the filing effective, it does not foreclose
the Commission from taking any action with respect to the filing and Elite represents that it will not assert Staff comments or
this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United
States.
Elite further acknowledges, that the action
of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective does not relieve Elite
from its full responsibility for the adequacy and accuracy of the disclosures in the filing.
Very truly yours,
ELITE PHARMACEUTICALS, INC.
By:
/s/ Nasrat Hakim
Nasrat Hakim
Chief Executive Officer